J9054 Bortezomib (boruzu) - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Bortezomib (boruzu)

Brand Name:

Boruzu

Strength:

0.1mg

HCPCS:

J9054

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Proteasome Inhibitor

Minor Drug Class:

26S

Oral (Y/N):

No

FDA Approval Year:

2024

FDA Discontinuation Year:

CMS Effective Date:

March 26, 2025

CMS Discontinuation Date:

Status:

In Use